| Numbers of participants1 | Crude odds ratios2 | Adjusted odds ratios2 | |||
---|---|---|---|---|---|---|
Not retained N = 235 N (%) | Retained N = 776 N (%) | Estimate (95% CI) | P-value < 0.01 | Estimate (95% CI) | P-value < 0.01 | |
Age | Â | Â | Â | Â | Â | Â |
 18–24 | 49 (21.3) | 90 (11.8) | 0.50 (0.36–0.70) |  | 0.48 (0.34–0.68) |  |
 25–34 | 105 (45.7) | 388 (51.1) | reference |  | Combined reference3 |  |
 35–44 | 57 (24.8) | 224 (29.5) | 1.06 (0.91–1.24) |  |  | |
 45 +  | 19 (8.3) | 58 (7.6) | 0.82 (0.46–1.44) |  |  | |
Sex | Â | Â | Â | 0.22 | Â | Â |
 Female | 112 (47.7) | 416 (53.7) | reference |  |  |  |
 Male | 123 (52.3) | 359 (46.3) | 0.79 (0.53–1.16) |  |  |  |
WHO stage | Â | Â | Â | 0.33 | Â | Â |
 I | 144 (70.6) | 524 (69.3) | reference |  |  |  |
 II | 42 (20.6) | 199 (26.3) | 1.30 (0.79–2.18) |  |  |  |
 III–IV | 18 (8.8) | 33 (4.4) | 0.56 (0.27–1.17) |  |  |  |
Entry point | Â | Â | Â | 0.32 | Â | Â |
 Facility | 118 (53.4) | 343 (46.7) | reference |  |  |  |
 Outreach | 103 (46.6) | 392 (53.3) | 1.30 (0.78–2.16) |  |  |  |
Phase | Â | Â | Â | 0.06 | Â | 0.05 |
 Pre-intervention | 166 (70.6) | 440 (56.7) | reference |  |  |  |
 Intervention | 69 (29.4) | 336 (43.3) | 1.84 (0.97–3.49) |  | 1.88 (1.00–3.54) |  |